Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: A systematic review and meta-analysis

BMC Urology

Volumn 14, Issue 1, 2014, Pages

  Botrel, Tobias Engel Ayer ^a,b   Clark, Otávio ^a,b   Dos Reis, Rodolfo Borges ^b   Pompeo, Antônio Carlos Lima ^b   Ferreira, Ubirajara ^b   Sadi, Marcus Vinicius ^b   Bretas, Francisco Flávio Horta ^b  

^a Evidencias Consulting   (Brazil)

^b Comitê Brasileiro de Estudos em Uro Oncologia ^*  (Brazil)

Author keywords

Androgen deprivation; Prostate cancer; Systematic review

Indexed keywords

ANDROGEN ANTAGONISTS; CAUSALITY; COMORBIDITY; DISEASE-FREE SURVIVAL; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PREVALENCE; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK FACTORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME;

EID: 84892691143     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-14-9     Document Type: Article

References (65)

1. The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight. Tunn U, BJU Int 2007 99 Suppl 1 19 22 discussion 3-4 17229164 (Pubitemid 44952824)
2. National Cancer Institute, Prostate Cancer Treatment (PDQ®). General Information About Prostate Cancer http://www.cancer.gov/cancertopics/pdq/ treatment/prostate. Accessed on 16 December 2013
3. Emerging cardiometabolic complications of androgen deprivation therapy. Choong K, Basaria S, Aging Male 2010 13 1 1 9 10.3109/13685530903410625 20148744
4. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Harle LK, Maggio M, Shahani S, Braga-Basaria M, Basaria S, Clin Adv Hematol Oncol 2006 4 9 687 696 17099626 (Pubitemid 44560316)
5. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature. Abrahamsson PA, Eur Urol 2010 57 1 49 59 10.1016/j.eururo.2009.07.049 19683858
6. International study into the use of intermittent hormone therapy in the treatment of carcinoma of the prostate: a meta-analysis of 1446 patients. Shaw GL, Wilson P, Cuzick J, Prowse DM, Goldenberg SL, Spry NA, et al. BJU Int 2007 99 5 1056 1065 10.1111/j.1464-410X.2007.06770.x 17346277 (Pubitemid 46587917)
7. National Institute for Health and Clinical Excellence, Prostate cancer: diagnosis and treatment February 2008. http://publications.nice.org.uk/prostate- cancer-cg58/guidance#metastatic-prostate-cancer. Accessed on 16 December 2013
8. Intermittent versus continuous androgen deprivation in prostate cancer. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. N Engl J Med 2013 368 14 1314 1325 10.1056/NEJMoa1212299 23550669
9. Intermittent androgen suppression for rising PSA level after radiotherapy. Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, et al. N Engl J Med 2012 367 10 895 903 10.1056/NEJMoa1201546 22931259
10. A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients with PSA progression after radical therapy: NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/UK Intercontinental Trial CRUKE/01/013. Klotz L, O' Callaghan CJ, Ding K, Dearnaley DP, Higano CS, Horwitz EM, et al. J Clin Oncol 2011 2011 4514 ASCO Annual Meeting Abstracts Vol 29, No 15-suppl (May 20 Supplement)
11. The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL, J Urol 2012 187 6 2074 2081 10.1016/j.juro.2012.01.122 22498230
12. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects. Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL, Eur Urol 2013 63 1 111 120 10.1016/j.eururo.2012.07.040 22857983
13. Identifying relevant studies for systematic reviews. Dickersin K, Scherer R, Lefebvre C, BMJ 1994 309 6964 1286 1291 10.1136/bmj.309.6964.1286 7718048 (Pubitemid 24340510)
14. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. Higgins JPT, Green S, The Cochrane Library, Issue 4, 2006 Chichester, UK: John Wiley & Sons, Ltd 2006
15. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Castro AA, Clark OA, Atallah AN, Sao Paulo Med J 1999 117 3 138 139 10511734
16. Egger M, Smith GD, Altman D, Systematic Reviews in Health Care London: BMJ Books 2001
17. Review Manager (RevMan), [Computer program]. Version 5.1 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration 2011
18. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Parmar MK, Torri V, Stewart L, Stat Med 1998 17 24 2815 2834 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3. 0.CO;2-8 9921604 (Pubitemid 28562978)
19. Measuring inconsistency in meta-analyses. Higgins JP, Thompson SG, Deeks JJ, Altman DG, BMJ 2003 327 7414 557 560 10.1136/bmj.327.7414.557 12958120 (Pubitemid 37088507)
20. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis. Yang K, Wang YJ, Chen XR, Chen HN, Clin Drug Investig 2010 30 4 229 241 10.2165/11532260-000000000-00000 20225906
21. Analysing and presenting results. Deeks JJHJ, Altman DG, Cochrane Handbook for Systematic Reviews of In- terventions (ed 4.2.6 [updated September 2006]) Chichester, United Kingdom: John Wiley & Sons, Ltd, Higgins JP, Green S, 2006
22. Meta-analysis in clinical trials. DerSimonian R, Laird N, Control Clin Trials 1986 7 3 177 188 10.1016/0197-2456(86)90046-2 3802833 (Pubitemid 17189972)
23. Bias in meta-analysis detected by a simple, graphical test. Egger M, Davey Smith G, Schneider M, Minder C, BMJ 1997 315 7109 629 634 10.1136/bmj.315.7109.629 9310563 (Pubitemid 27387172)
24. Using numerical results from systematic reviews in clinical practice. McQuay HJ, Moore RA, Ann Intern Med 1997 126 9 712 720 10.7326/0003-4819-126-9- 199705010-00007 9139558 (Pubitemid 27184043)
25. Numbers needed to treat derived from meta-analyses-sometimes informative, usually misleading. Smeeth L, Haines A, Ebrahim S, BMJ 1999 318 7197 1548 1551 10.1136/bmj.318.7197.1548 10356018 (Pubitemid 29255803)
26. Meta-analysis, Simpson's paradox, and the number needed to treat. Altman DG, Deeks JJ, BMC Med Res Methodol 2002 2 3 10.1186/1471-2288-2-3 11860606
27. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. Ann Intern Med 2009 151 4 65 W94 19622512
28. Intermittent endocrine therapy for advanced prostate cancer. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr, Cancer 1986 58 11 2546 2550 10.1002/1097-0142(19861201)58:11<2546::AID-CNCR2820581131>3.0.CO;2-N 2429759 (Pubitemid 17191621)
29. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K, Urology 1995 45 5 839 844 discussion 44-5 10.1016/S0090-4295(99)80092-2 7538246
30. Intermittent androgen suppression with leuprolide and flutamide for prostate cancer: a pilot study. Higano CS, Ellis W, Russell K, Lange PH, Urology 1996 48 5 800 804 10.1016/S0090-4295(96)00381-0 8911533 (Pubitemid 26409365)
31. Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Oliver RT, Williams G, Paris AM, Blandy JP, Urology 1997 49 1 79 82 10.1016/S0090-4295(96) 00373-1 9000190 (Pubitemid 27049707)
32. Treatment of mid- and lower ureteric calculi: extracorporeal shock-wave lithotripsy vs laser ureteroscopy. A comparison of costs, morbidity and effectiveness. Bierkens AF, Hendrikx AJ, De La Rosette JJ, Stultiens GN, Beerlage HP, Arends AJ, et al. Br J Urol 1998 81 1 31 35 10.1046/j.1464-410x. 1998.00510.x 9467473 (Pubitemid 28316494)
33. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Grossfeld GD, Small EJ, Carroll PR, Urology 1998 51 1 137 144 10.1016/S0090-4295(97)00488-3 9457309 (Pubitemid 28092526)
34. da Silva Jr F C, Calais Da Silva F, Brausi M, Goncalves F, Kliment J, Queimadelos A, et al. Pooled Analysis of two protocols of intermittent hormonal therapy in advanced prostatic cancer: AUA 2013 Annual Meeting 777
35. Intermittent versus continuous androgen suppression for prostatic cancer. De Conti P, Atallah Alvaro N, Arruda Homero O, Soares Bernardo GO, El Dib Regina P, Wilt Timothy J, Cochrane Database Syst Rev 2007 4 Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005009.pub2/abstract
36. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, et al. J Clin Oncol 2007 25 12 1596 1605 10.1200/JCO.2006.10.1949 17404365 (Pubitemid 46733088)
37. EAU guidelines on prostate cancer. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. Eur Urol 2008 53 1 68 80 10.1016/j.eururo.2007. 09.002 17920184 (Pubitemid 350166735)
38. Androgen deprivation for advanced prostate cancer. Heidenreich A, Pfister D, Ohlmann CH, Engelmann UH, Urologe A 2008 47 3 270 283 10.1007/s00120-008- 1636-2 18273599
39. EAU guidelines on prostate cancer. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. Actas Urol Esp 2009 33 2 113 126 10.1016/S0210-4806(09)74110-5 19418833
40. Intermittent versus continuous androgen suppression therapy: do we have consensus yet? Buchan NC, Goldenberg SL, Curr Oncol 2010 17 Suppl 2 45 S48 20882133
41. Intermittent androgen deprivation-questions remain. Keizman D, Carducci MA, Nat Rev Urol 2009 6 8 412 414 10.1038/nrurol.2009.145 19657375
42. Safety and tolerability of intermittent androgen deprivation therapy: a literature review. Gruca D, Bacher P, Tunn U, Int J Urol 2012 19 7 614 625 10.1111/j.1442-2042.2012.03001.x 22435512
43. Intermittent LHRH therapy in the management of castrate-resistant prostate cancer (CRPCa): results of a multi-institutional randomized prospective clinical trial. Organ M, Wood L, Wilke D, Skedgel C, Cheng T, North S, et al. Am J Clin Oncol 2013 36 6 601 605 10.1097/COC.0b013e31825d5664 22868247
44. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. da Silva FE C, Bono AV, Whelan P, Brausi M, Marques Queimadelos A, Martin JA, et al. Eur Urol 2009 55 6 1269 1277 10.1016/j.eururo.2009.02.016 19249153
45. Phase III study of intermittent MAB vs continuos MAB. da Silva FM C, da SIlva F C, Bono A, Whelan P, Brausi M, Queimadelos A, et al. J Urol 2011 185 4 288 April 2011, AUA 2011 abstract 716
46. Intermittent is as effective as continuous androgen deprivation in patients with PSA relapse after radical prostatectomy. Tunn U, Kurek R, Keinle E, et al. J Urol 2004 171 384 Abstract 1458 10.1097/01.ju.0000102933.25905.08 14665937 (Pubitemid 37549190)
47. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy. Tunn UW, Canepa G, Kochanowsky A, Kienle E, Prostate Cancer Prostatic Dis 2012 15 3 296 302 10.1038/pcan.2012.12 22733160
48. Verhagen PCMS, Wissenburg LD, Wildhagen MF, et al. Quality of life effects of intermittent and continuous hormonal therapy by cyproterone acetate (CPA) for metastatic prostate cancer [abstract 541] Milan, Italy: Presented at: 23rd Annual Congress of the European Association of Urology; March 26-29, 2008 2008
49. Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: Results of a randomized trial. Verhagen PCMS, Wildhagen MF, Verkerk A, Bolle WABM, et al. Eur Urol 2013 12 680 10.1016/S1569-9056(13)61162-8
50. Intermittent hormonal therapy in the treatment of metastatic prostate cancer: a randomized trial. Mottet N, Van Damme J, Loulidi S, Russel C, Leitenberger A, Wolff JM, BJU Int 2012 110 9 1262 1269 10.1111/j.1464-410X.2012. 11120.x 22502816
51. Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. de Leval J, Boca P, Yousef E, Nicolas H, Jeukenne M, Seidel L, et al. Clin Prostate Cancer 2002 1 3 163 171 10.3816/CGC.2002.n.018 15046691 (Pubitemid 37012397)
52. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer. Langenhuijsen JF, Badhauser D, Schaaf B, Kiemeney LA, Witjes JA, Mulders PF, Urol Oncol 2011 9
53. Langenhuijsen JF, Schasfoort EMC, Heathcote P, et al. Intermittent androgen suppression in patients with advanced prostate cancer: an update of the TULP survival data [abstract 538] Milan, Italy: Presented at: 23rd Annual Congress of the European Association of Urology; March 26-29, 2008 2008
54. Metastatic adenocarcinoma of the prostate: comparison between continuous and intermittent hormonal treatment. Hering F, Rodrigues PRT, Lipay MA, Nesrallah L, Srougi M, Braz J Urol 2000 26 276 282
55. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, et al. J Clin Oncol 2006 24 24 3984 3990 10.1200/JCO.2006.06.4246 16921051 (Pubitemid 46630748)
56. Miller K, Steiner U, Lingnau A, et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer [abstract 5105] Chicago, IL, USA: Presented at: American Society of Clinical Oncology; June 1-5 2007
57. Continuous versus six months a year maximal androgen blockade in the management of prostate cancer: a randomised study. Irani J, Celhay O, Hubert J, Bladou F, Ragni E, Trape G, et al. Eur Urol 2008 54 2 382 391 10.1016/j.eururo.2008.02.024 18339475
58. Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade: results from a randomised phase 3 study by the south European uroncological group. Silva FC, Silva FM, Goncalves F, Santos A, Kliment J, Whelan P, et al. Eur Urol 2013
59. Prostate cancer, Guideline for the management of clinically localized prostate cancer 2007 update. American Urological Association. Web site. http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/ main-reports/proscan07/content.pdf
60. Guidelines on prostate cancer. Heidenreich A, Bastian PJ, Bellmunt J, et al. Eur Association Urol Web site http://wwwuroweborg/gls/pdf/ 08%20Prostate%20Cancer-LR%20March%2013th%202012pdf
61. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Sciarra A, Abrahamsson PA, Brausi M, Galsky M, Mottet N, Sartor O, et al. Eur Urol 2013 64 5 722 730 10.1016/j.eururo.2013.04. 020 23628492
62. Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. Niraula S, Le LW, Tannock IF, J Clin Oncol 2013 31 16 2029 2036 10.1200/JCO.2012.46.5492 23630216
63. Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis. Tsai HT, Penson DF, Makambi KH, Lynch JH, Van Den Eeden SK, Potosky AL, Urology 2013 82 2 327 334 10.1016/j.urology.2013.01.078 23896094
64. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, et al. J Clin Oncol 2008 26 1 44 53 10.1200/JCO.2007.11.3787 18165639
65. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Jespersen CG, Norgaard M, Borre M, Eur Urol 2013